Pipeline

Overview

Arrien Pharmaceuticals is focused on the drug discovery and development of innovative targeted therapeutics for the treatment of human cancers, autoimmune and neurodegenerative diseases.

Clinical Program
ARN-6039
Inhibitor of ROR-γt (Psoriasis, RA and MS)
Partner: Worldwide exclusive license granted to Boston Pharmaceuticals in 2017.

Mechanism of Action: The nuclear hormone receptor retinoic acid-related orphan receptor gamma t (ROR-γt) is a transcription factor (TF) specific to TH17 cells that produce interleukin (IL)-17 and have been implicated in a wide range of autoimmunity.

ARN-3261
Inhibitor of SIK2 (Salt Inducible Kinase 2)
To be investigated in a Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors (TNBC, DLBCL & Prostate) and AML cancers. An IND being approved to initiate the Phase 1a/1b trials beginning of Q1 2019.

The pipeline above provides the most advanced programs in the areas of Oncology, Autoimmune, CNS/Neurodegenerative diseases and stages of drug development process.